

28 September 2023

ASX ANNOUNCEMENT

General Meeting – Results of Meeting

Set out below are the results of the General Meeting held earlier today. All resolutions put to the meeting were decided by a poll.

Resolution	Resolution	Result
1	Removal of Donald Williams as a director of the Company	Passed as an ordinary resolution
2	Removal of Amit Patel as a director of the Company	Passed as an ordinary resolution
3	Removal of David Anderson as a director of the Company	Passed as an ordinary resolution
4	Removal of Daniel Sharp as a director of the Company	Passed as an ordinary resolution
5	Appointment of McGregor Grant as a director of the Company	Passed as an ordinary resolution
6	Appointment of Christine Emmanuel-Donnelly as a director of the Company	Passed as an ordinary resolution
7	Appointment of Andrew Grant as a director of the Company	Passed as an ordinary resolution
8	Appointment of Janelle Delaney as a director of the Company	Passed as an ordinary resolution

In accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2 the results of the General Meeting are provided in the attached document.

Approved for release by the Company Secretary, Leanne Ralph.

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

GENERAL MEETING
Thursday, 28 September, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Direct vote (as at proxy close):		Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	For	Against	Abstain **	
1	REMOVAL OF DONALD ALLEN WILLIAMS AS DIRECTOR OF THE COMPANY	NA	401,488,958 27.47%	367,474,124 25.14%	35,302,035 2.42%	0	449,706,739 30.77%	207,692,924 14.21%	853,709,530 58.30%	610,519,890 41.70%	300,000	Carried
2	REMOVAL OF AMIT PATEL AS DIRECTOR OF THE COMPANY	NA	401,486,291 27.47%	367,476,791 25.14%	35,302,035 2.42%	0	447,301,739 30.60%	210,097,924 14.37%	851,301,863 58.14%	612,927,557 41.86%	300,000	Carried
3	REMOVAL OF DAVID ANDERSON AS DIRECTOR OF THE COMPANY	NA	386,142,864 26.42%	382,820,218 26.19%	35,302,035 2.42%	0	455,172,325 31.14%	202,227,338 13.84%	842,280,385 57.51%	622,241,795 42.49%	7,240	Carried
4	REMOVAL OF DANIEL HOWARD SHARP AS DIRECTOR OF THE COMPANY	NA	398,179,506 27.24%	370,783,576 25.37%	35,302,035 2.42%	0	442,927,721 30.30%	214,471,942 14.67%	842,072,423 57.50%	622,449,757 42.50%	7,240	Carried
5	APPOINTMENT OF MCGREGOR GRANT AS DIRECTOR OF THE COMPANY	NA	409,075,596 27.99%	359,884,486 24.62%	35,305,035 2.42%	0	464,518,107 31.78%	192,881,556 13.20%	876,407,536 59.84%	588,121,884 40.16%	0	Carried
6	APPOINTMENT OF CHRISTINE EMMANUEL-DONNELLY AS DIRECTOR OF THE COMPANY	NA	425,433,032 29.11%	343,527,050 23.50%	35,305,035 2.42%	0	437,565,099 29.94%	219,834,564 15.04%	865,511,964 59.11%	598,717,456 40.89%	300,000	Carried
7	APPOINTMENT OF ANDREW GRANT AS DIRECTOR OF THE COMPANY	NA	402,624,880 27.55%	366,335,202 25.06%	35,305,035 2.42%	0	432,536,343 29.59%	224,863,320 15.38%	836,133,659 57.10%	628,095,761 42.90%	300,000	Carried
8	APPOINTMENT OF JANELLE DELANEY AS DIRECTOR OF THE COMPANY	NA	370,196,357 25.33%	398,763,725 27.28%	35,305,035 2.42%	0	435,090,407 29.77%	222,309,256 15.21%	806,259,200 55.06%	657,970,220 44.94%	300,000	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item